African Journal of Parasitology Research

ISSN 2756-3391

African Journal of Parasitology Research | Vol. 14, No. 8, August 2026 | pp. 793–799

DOI: 10.46882/AJPR/140793

Article Type: Full Length Research Paper

Title: Detection of artemisinin-resistant Plasmodium falciparum kelch13 propeller domain mutations in uncomplicated malaria cases

Names of Authors: Alejandro Morales-Vega¹*, Beatriz Silva-Costa², Mateo Alvarez-Rios³

Authors’ Affiliations: ¹Institute of Tropical Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru. ²Department of Parasitology, University of São Paulo, 05508 São Paulo, Brazil. ³National Center for Tropical Diseases, Santa Cruz, Bolivia.

Background: Artemisinin partial resistance in Plasmodium falciparum threatens the effectiveness of artemisinin-based combination therapies (ACTs), the cornerstone of uncomplicated malaria treatment. Mutations in the propeller domain of the parasite kelch13 (k13) gene are the principal validated molecular markers of this phenotype. Continuous molecular surveillance is therefore essential to detect resistance before it translates into widespread treatment failure.

Methods: In this cross-sectional molecular surveillance study, 315 dried blood spot (DBS) samples were collected from febrile patients with uncomplicated falciparum malaria confirmed by rapid diagnostic test and Giemsa-stained thick blood smear. Genomic DNA was extracted and subjected to nested polymerase chain reaction (PCR) spanning codons 427 to 709 of Pfk13, followed by Sanger sequencing. Parasite density, amplification success, genotype frequencies, and day-3 parasite positivity were analysed.

Results: The geometric mean parasite density was 14,820 parasites per microlitre. PCR yielded the expected 849 base-pair amplicon in 308 of 315 samples (97.8%). Among sequenced isolates, 289 (93.8%) were wild-type and 19 (6.2%) carried non-synonymous propeller-domain mutations: C580Y in 11 (3.6%), R539T in 5 (1.6%), and Y493H in 3 (1.0%). Patients harbouring mutant alleles more frequently exhibited delayed parasite clearance on day 3 post-treatment than those with wild-type infections.

Conclusion: Validated k13 mutations associated with artemisinin partial resistance circulate at a detectable frequency in this population. The findings support integrating routine k13 genotyping with therapeutic efficacy studies to guide antimalarial drug policy, preserve ACT effectiveness, and prevent entrenched resistance.

Keywords: Plasmodium falciparum; artemisinin resistance; kelch13 gene; malaria surveillance; ACT; molecular epidemiology


Manuscript Timeline: Received: February 03, 2026; Revised: March 11, 2026; Accepted: April 19, 2026; Published: August 28, 2026